SEARCH

SEARCH BY CITATION

References

  • 1
    Huang JQ, Hunt RH. Are one-week anti-Helicobacter pylori treatments more effective in patients with peptic ulcer disease than in those with non ulcer dyspepsia? A meta-analysis. Am J Gastroenterol 1998; 93: 1639.
  • 2
    De Francesco V, Sgarro C, Cela E, et al. Helicobacter pylori eradication rates in non-ulcer dyspepsia (NUD) and duodenal ulcer (DU) patients. Gut 2001; 48(Suppl. 11): A94(Abstract).
  • 3
    Gisbert JP, Marcos S, Gisbert JL, Pajares JM. Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. Eur J Gastroenterol Hepatol 2001; 13(11): 13037.
  • 4
    Van Doorn LJ, Schneeberger PM, Nohuan N, Plaisier AP, Quint WGV, De Boer WA. Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut 2000; 46: 3216.
  • 5
    Broutet N, Marais A, Lamouliatte H, et al. cag A status and eradication treatment outcome of anti-Helicobacter pylori triple therapies in patients with non-ulcer dyspepsia. J Clin Microbiol 2001; 39(4): 131922.
  • 6
    Broutet N, Tchamgoué S, Pereira E, Lamouliatte H, Salamon R, Mègraud F. Risk factors for failure of Helicobacter pylori therapy — results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003; 17: 99109.
  • 7
    Russo F, Berloco P, Cuomo R, et al. Helicobacter pylori strains and histologically related lesions affect the outcome of triple eradication therapy: a study from southern Italy. Aliment Pharmacol Ther 2003; 17: 18.
  • 8
    Zullo A, Rinaldi V, Winn S, et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 7158.
  • 9
    De Francesco VA, Zullo A, Hassan C, et al. Two new treatment regimens for Helicobacter pylori eradication: a randomised study. Digest Liver Dis 2001; 33(8): 6769.
  • 10
    De Francesco V, Panella C, Margiotta M, Faleo D, Ierardi E. Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with non-ulcer dyspepsia? Am J Gastroenterol 2002; 97: 910.
  • 11
    Zullo A, Vaira D, Vakil N, et al. High rates of Helicobacter pylori with new sequential treatment. Aliment Pharmacol Ther 2003; 17: 71926.
  • 12
    De Boer WA, Tytgat GN. Should anti Helicobacter therapy be different in patients with dyspepsia compared with patients with peptic ulcer diathesis? Eur J Gastroenterol Hepatol 2001; 13: 12814.
  • 13
    De Francesco V, Ierardi E, Zullo A, et al. Triple therapy prolongation is of doubtful advantage for Helicobacter pylori eradication. Digest Liver Dis 2003; 35(4S): S104.
  • 14
    Working Party of the European Helicobacter pylori Study Group. Technical annex: tests used to assess Helicobacter pylori infection. In: Guidelines for clinical trials in Helicobacter pylori infection. Gut 1997; 41(2S): S108.
  • 15
    Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston, 1994. Am J Surg Pathol 1996; 20: 116181.
  • 16
    Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther 2002; 16: 124959.
  • 17
    Lin TT, Yeh CT, Yang E, Chen PC. Detection of Helicobacter pylori by polymerase chain reaction assay using gastric biopsy specimens taken for CLO-test. J Gastroenterol 1996; 31: 32932.
  • 18
    Clayton CL, Kleanthous H, Coates PJ, Morgan DD, Tabaqchali S. Sensitive detection of Helicobacter pylori by using polymerase chain reaction. J Clin Microbiol 1992; 30: 192200.
  • 19
    Tummuru MKR, Cover TL, Blaser MJ. Cloning and expression of a high molecular mass major antigen of Helicobacter pylori. Infect Immun 1993; 61: 1799809.
  • 20
    Atherton JC, Cao P, Peek RM, Tummuru MKR, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori: association of specific vacA types with cytotoxin production and peptic ulcer secretion protein. J Biol Chem 1995; 270: 17 771–7.
  • 21
    Labigne A, Lamouliatte H, Birac C. Distribution of the CagA gene among Helicobacter pylori strains associated with peptic ulcer. Am J Gastroenterol 1994; 89: 1326.
  • 22
    Maeda S, Yoshida T, Ikenoue T, et al. Structure of cag pathogenicity island in Japanese Helicobacter pylori isolates. Gut 1999; 44: 33641.
  • 23
    Censini S, Lange Z, Xiang JE, et al. Cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci USA 1996; 93: 14 648–53.
  • 24
    Ierardi E, Margiotta M, Monno R, et al. A new semiquantitive method of quantifying Helicobacter pylori. J Clin Gastroenterol 2002; 35: 3758.
  • 25
    Rinaldi V, Zullo A, Pugliano F, Valente C, Diana F, Attili AF. The management of failed dual or triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 1997; 11: 92933.
  • 26
    Moschkowitz FM, Peled Y, Santo M, et al. Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut 1995; 36: 8457.
  • 27
    Mégraud F, Lamouliatte H, Delchier JC., et al. Helicobacter pylori resistance to antimicrobial agents after failure of an initial eradication treatment and impact on results of second-line treatment strategies: a multicenter prospective study. Gut 2001; 49(Suppl. II): A83(Abstract).
  • 28
    Paul R, Postius S, Melchers K, Schafer KP. Mutations of Helicobacter pylori genes rdxA and pbp1 cause resistance against metronidazole and amoxicillin. Antimicrob Chemother 2001; 45: 9625.
  • 29
    Iwao T, Toyonaga A, Ikegami M, et al. Gastric mucosal blood flow after smoking in healthy human beings assessed by laser Doppler flowmetry. Gastrointest Endosc 1993; 39: 4003.
  • 30
    Kamada T, Haruma K, Miyoshi E, et al. Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin and clarithromycin increases the eradication rate of Helicobacter pylori in smokers. Aliment Pharmacol Ther 2000; 14: 108994.